Scholarlink

<p>Glioblastoma (GBM), <i>IDH</i>-wildtype, is the most common and aggressive primary brain tumor in adults. According to the 2021 WHO classification, <i>IDH</i>-wildtype diffuse gliomas with a <i>TERT</i> promoter (<i>TERT</i>p) mutation, <i>EGFR</i> amplification, or combined whole-chromosome 7 gain and 10 loss (+ 7/− 10) are designated as GBM, <i>IDH</i>-wildtype, regardless of histological grade, and termed molecular GBM (mol-GBM). Although this redefinition has been widely adopted, the prognostic implications of mol-GBM remain uncertain. To clarify its clinical relevance, we retrospectively analyzed adult patients treated at our institution between 2010 and 2024. We identified 22 cases of <i>TERT</i>p-mutant mol-GBM (grade 2, <i>n</i> = 7; grade 3, <i>n</i> = 15) and compared them with 218 cases of <i>TERT</i>p-mutant histologically confirmed GBM (hist-GBM). Overall survival (OS) was assessed using Kaplan–Meier analysis, log-rank test, and propensity score matching (PSM) adjusted for age, preoperative Karnofsky Performance Status, extent of resection, adjuvant therapy, and <i>MGMT</i> methylation status. Mol-GBM showed significantly longer OS than hist-GBM after PSM (<i>p</i> = 0.019), with grade 2&#xa0;mol-GBM showing particularly favorable survival (<i>p</i> = 0.008). Cox regression analysis revealed mol-GBM as an independent predictor of good prognosis (hazard ratio: 0.37, 95% confidence interval: 0.22–0.62, <i>p</i> &lt; 0.001). Across all <i>TERT</i>p-mutant GBMs, a non-contrast-enhancing (non-CE) MRI phenotype correlated with significantly longer OS than CE tumors, persisting after PSM (<i>p</i> = 0.004). Within mol-GBM, an isolated <i>TERT</i>p mutation did not stratify OS, whereas <i>CDKN2A/B</i> homozygous deletion predicted worse outcomes (<i>p</i> = 0.026). DNA methylation profiling classified most mol-GBM as GBM, <i>IDH</i>-wildtype methylation class, and all cases clustered with GBM on t-SNE, confirming molecular proximity to GBM. Integrated methylation and RNA-seq analysis revealed <i>WIF-1</i> promoter hypermethylation with reduced expression in grade 3 cases. These findings suggest that histological grade 2 and the non-CE phenotype may provide exploratory prognostic information in <i>TERT</i>p-mutant mol-GBM, complementary to DNA methylation classification.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Histological grade 2 and non-contrast-enhancing phenotype provide prognostic information complementary to DNA methylation classification in TERTp-mutant molecular glioblastomas

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月4日

查看全文
  • Hiroyuki Sueyoshi,
  • Kenji Fujimoto,
  • Katsumi Fujita,
  • Kazuhito Tanaka,
  • Hirotaka Inoue,
  • Rin Yamada,
  • Takahiro Yamamoto,
  • Yutaka Nakachi,
  • Jun-ichiro Kuroda,
  • Naoki Shinojima,
  • Kazuya Iwamoto,
  • Yoshiki Mikami,
  • Akitake Mukasa

摘要

Glioblastoma (GBM), IDH-wildtype, is the most common and aggressive primary brain tumor in adults. According to the 2021 WHO classification, IDH-wildtype diffuse gliomas with a TERT promoter (TERTp) mutation, EGFR amplification, or combined whole-chromosome 7 gain and 10 loss (+ 7/− 10) are designated as GBM, IDH-wildtype, regardless of histological grade, and termed molecular GBM (mol-GBM). Although this redefinition has been widely adopted, the prognostic implications of mol-GBM remain uncertain. To clarify its clinical relevance, we retrospectively analyzed adult patients treated at our institution between 2010 and 2024. We identified 22 cases of TERTp-mutant mol-GBM (grade 2, n = 7; grade 3, n = 15) and compared them with 218 cases of TERTp-mutant histologically confirmed GBM (hist-GBM). Overall survival (OS) was assessed using Kaplan–Meier analysis, log-rank test, and propensity score matching (PSM) adjusted for age, preoperative Karnofsky Performance Status, extent of resection, adjuvant therapy, and MGMT methylation status. Mol-GBM showed significantly longer OS than hist-GBM after PSM (p = 0.019), with grade 2 mol-GBM showing particularly favorable survival (p = 0.008). Cox regression analysis revealed mol-GBM as an independent predictor of good prognosis (hazard ratio: 0.37, 95% confidence interval: 0.22–0.62, p < 0.001). Across all TERTp-mutant GBMs, a non-contrast-enhancing (non-CE) MRI phenotype correlated with significantly longer OS than CE tumors, persisting after PSM (p = 0.004). Within mol-GBM, an isolated TERTp mutation did not stratify OS, whereas CDKN2A/B homozygous deletion predicted worse outcomes (p = 0.026). DNA methylation profiling classified most mol-GBM as GBM, IDH-wildtype methylation class, and all cases clustered with GBM on t-SNE, confirming molecular proximity to GBM. Integrated methylation and RNA-seq analysis revealed WIF-1 promoter hypermethylation with reduced expression in grade 3 cases. These findings suggest that histological grade 2 and the non-CE phenotype may provide exploratory prognostic information in TERTp-mutant mol-GBM, complementary to DNA methylation classification.